Related Experiment Video
Updated: Oct 19, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
The effect of rosuvastatin on cardiogenic cerebral infarction
1The First Department of Neurology, Tangshan People's Hospital Tangshan, Hebei Province, China.
Insights
Rosuvastatin significantly improved neurological function and treatment efficacy in patients with cardiogenic cerebral infarction. This statin therapy also positively impacted lipid profiles, inflammation, and oxidative stress markers.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Cardiogenic cerebral infarction poses a significant health risk, necessitating effective treatment strategies.
- Understanding the impact of statins on neurological recovery and underlying pathophysiological markers is crucial.
Purpose of the Study:
- To evaluate the efficacy of rosuvastatin in treating cardiogenic cerebral infarction.
- To assess rosuvastatin's effects on neurological function, lipid profiles, inflammation, and oxidative stress.
Main Methods:
- A cohort of 300 patients with cardiogenic cerebral infarction was randomized into two groups.
- The observation group received rosuvastatin plus routine treatment; the control group received routine treatment only.
- Neurological function (NIHSS, mRS), lipid levels, inflammatory markers (TNF-α, CRP), and oxidative stress (ox-LDL, SOD) were compared.
Main Results:
- The rosuvastatin group showed a higher total effective rate (84.7% vs. 74.0%) and significantly lower NIHSS and mRS scores.
- Rosuvastatin significantly reduced total cholesterol, triglycerides, LDL-C, and improved HDL-C levels.
- Inflammatory markers (TNF-α, CRP) and oxidative stress markers (ox-LDL) were reduced, while antioxidant SOD levels increased in the rosuvastatin group.
Conclusions:
- Rosuvastatin demonstrates significant therapeutic benefits for cardiogenic cerebral infarction patients.
- The drug improves neurological outcomes by favorably modulating lipid metabolism, inflammation, and oxidative stress.
Objective:
To investigate the effect of rosuvastatin on cardiogenic cerebral infarction and its related effects on patients' neurological function, lipid levels, inflammatory factor levels, and oxidative stress status.
Methods:
300 patients with cardiogenic cerebral infarction were recruited as the study cohort and randomly divided into an observation group and a control group. Routine treatment, including urinary kallikrein injections and bayaspirin tablets were given to the patients in the control group for one month. Rosuvastatin was given once a day in addition to the treatment the control group received to the patients in the observation group, also for one month. The two groups' treatment efficacies were compared. Also, the two groups' NIHSS and mRS scores, lipid and inflammatory factor levels, and their oxidative stress statuses were also compared.
Results:
The total effective rate in the observation group was significantly higher than it was in the control group (74.0% vs 84.7%, P=0.023). The NIHSS and mRS scores in the observation group were significantly lower than they were in the control group (all P<0.001). Compared with their levels after the treatment in the control group, the cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels in the observation group were significantly decreased and the high-density lipoprotein cholesterol (HDL-C) was significantly increased (all P<0.001). Moreover, after the treatment, the inflammatory factors, such as the tumor necrosis factor-alpha (TNF-α) and C-reactive protein (CRP) levels, and the oxidative stress status, such as the oxidatively modified low density lipoprotein (ox-LDL) levels, were significantly lower than they were in the control group, but the superoxide dimutase (SOD) levels were significantly higher.
Conclusions:
Rosuvastatin remarkably improves the treatment efficacy and neurological function in cardiogenic cerebral infarction patients, and is associated with the improvement of the lipid levels, the inflammatory response, and the oxidative stress status.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Acute Coronary Syndrome III: Diagnostic Studies